Navigation Links
Wounded Warriors a Focus of the 12th New Jersey Symposium on Biomaterials Science
Date:8/1/2014

Piscataway, NJ (PRWEB) August 02, 2014

For the past five years, the New Jersey Center for Biomaterials under the auspices of the Armed Forces Institute of Regenerative Medicine (AFIRM) has led a consortium of academic research organizations in the development of advanced treatment options for our severely wounded warriors. AFIRM is a multi-institutional, inter¬disciplinary network working to develop new products and therapies to treat severe injuries suffered by US servicemen and women in the current wars. The AFIRM teams, working in research laboratories and clinics across the country, are advancing biological therapies (including adult stem cells and growth factors), tissue and biomaterials engineering, and advanced transplantation methods. These new treatments will enable the body to repair, replace, restore and regenerate damaged tissues and organs.

The 12th New Jersey Symposium on Biomaterials Science will focus several presentations on the regeneration of nerves and muscle resulting from catastrophic peripheral nerve injury and muscular tissue loss for Wounded Warriors. These types of injuries to the body’s soft tissue are leading sources of lifelong disability. Extreme trauma from combat wounds can cause nerve injuries that create gaps in the nerves leading to the muscles of the limbs. The success in this work for our Wounded Warriors is readily translatable to injuries suffered by the civilian population resulting from industrial and automobile accidents.

Registration for the 12th NJ Symposium on Biomaterials Science is available at http://www.njbiomaterials.org/biomaterials-symposia.htm.

The New Jersey Center for Biomaterials (NJCBM) was founded in 1997. Based at Rutgers, the State University of New Jersey, the center spans academia, industry, and government. Staffed by biomaterial scientists, the Center works to improve health care and quality of life by developing advanced biomedical products for tissue repair and replacement as well as the delivery of pharmaceutical agents. The Center’s technologies have been translated into clinical and pre-clinical products including surgical meshes, cardiovascular stents, bone regeneration scaffolds, and ocular drug delivery systems.

Media Contact:

Louli Kourkounakis
(732) 445 0488 ext. 40001
symposium(at)dls(dot)rutgers(dot)edu

Read the full story at http://www.prweb.com/releases/2014/08/prweb12062870.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
2. Model Aviation Clubs Raise $76,000 for the Wounded Warrior Project
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
5. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
6. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
7. Vermillion Sharpens Focus and Streamlines Operations in 2012
8. Inverseon Focuses on Mucous and Smoking Cessation
9. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
10. Global Markets for Enzymes in Industrial Applications -- Focus on Europe
11. QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):